Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Medtronic (NYSE:MDT) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 158.62% over the past year to $1.50, which beat the estimate of $1.42.

Recap: Medtronic Q4 Earnings

Medtronic earnings and sales topped fiscal Q4 views. The medical technology company's EPS guidance was at best in line.

Medtronic Earnings Top, Guidance So-So With Stock In Buy Zone

DUBLIN, May 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188 billion, an increase of 37 percent as reported and 32 percent on an organic basis, which adjusts for the $241 million benefit of foreign currency translation.

Medtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend Increase

New No Fingerstick 1  Sensor Integrates with Both the MiniMed 780G System and the Smart InPen System DUBLIN, May 26, 2021 /PRNewswire/ --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark for expanded functionality of the company's InPen™ smart2 insulin pen for multiple daily injections (MDI). The company also announced CE Mark for its Guardian™ 4 sensor3, which requires no fingersticks1 for calibration or diabetes treatment decisions.

Medtronic Secures Two CE Mark Approvals for Guardian 4 Sensor & for InPen MDI Smart Insulin Pen

Best Buy

NVIDIA

Pure Storage

With the Memorial Day holiday coming up, the flood of earnings reports will be slowing to a trickle until a couple of weeks after the June quarter closes.

Earnings Previews: Best Buy, Medtronic, Nvidia, Pure Storage

Butterfly Network

Microsoft

These attractive AI stocks relate to the healthcare sector, and explore the application of AI in diagnostics, surgery, among others. The post 4 AI Healthcare Stocks Transforming the Medical Industry appeared first on InvestorPlace.

4 AI Healthcare Stocks Transforming the Medical Industry

Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.

Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings

Apple

Garmin

Rising demand for smart medical devices due to their convenience of providing active monitoring of patients makes it wise to look at names like Apple (AAPL), Garmin (GRMN) and Medtronic (MDT).

3 Stocks to Watch on Rising Demand for Smart Medical Devices

Abbott Labs

Ameriprise Financial

Air Products and Chemicals

Cincinnati Financial

Johnson & Johnson

Lumen Technologies

Altria

Philip Morris

Starbucks

Total

Texas Instruments

Visa

Forecasting the income provided from a dividend growth portfolio has proven remarkably accurate, regardless of tweaks to investing philosophy. Long range predictions of an individual stock price is akin to fortune telling, yet in aggregate, the stock market increases with consistency over time.

The Perfect Predictive Power Of Dividends

The Low Risk Trial has demonstrated non-inferiority of Medtronic's (MDT) TAVR system over open heart surgery.

Medtronic (MDT) Reveals Promising Results From Evolut Trial

Medtronic Plc (NYSE: MDT) has announced the complete two-year outcomes from a low-risk trial comparing the Evolut transcatheter aortic valve replacement (TAVR) system to open-heart surgery in characteristically younger, healthier aortic stenosis patients. Data were presented at the EuroPCR 2021 e-Course.

Medtronic's Evolut Aortic Valve Replacement Shows Positive Outcomes Even After Two Years

DUBLIN, May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™ transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. Presented virtually today as a late-breaking clinical trial at the EuroPCR 2021 e-Course, results showed the Evolut TAVR platform was non inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for TAVR versus 6.3% for surgery; p< 0.0001 for non-inferiority), and trended the same or lower on all critical events, confirming the earlier Bayesian statistical analysis presented at the American College of Cardiology (ACC) 68th Annual Scientific Session in 2019.

Medtronic Evolut™ TAVR System Shows Strong Performance at Two Years in Low Risk Trial

Medtronic Launches New GSR-DEFINE Study to Expand Real-World Data to 5,000 Patients DUBLIN, May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the Global SYMPLICITY Registry (GSR) indicating that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System was associated with clinically significant and sustained blood pressure reductions in a real-world hypertensive patient population through three years. Results from the prospective, single-arm, global, observational study are being presented as a Late-Breaking Clinical Trial session at the 2021 EuroPCR Annual Meeting.

Late Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients

In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.

Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic

Anthem

Cigna

CVS Health

Henry Schein

IQVIA Hlds

UnitedHealth Group

The Benzinga Global Small Cap Conference on May 13 featured presentations from publicly-traded companies and educational segments for investors. Among the featured segments was one from Chris Capre on how to trade healthcare trends.

How To Trade These 7 Healthcare Stocks and ETF Says 2ndSkiesForex's Chris Capre

DUBLIN, May 14, 2021 /PRNewswire/ -- New findings from an American College of Cardiology's (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around treatment options for heart valve disease (HVD). Results from the ACC CardioSurve panelist survey, sponsored by Medtronic (NYSE: MDT), and conducted by the American College of Cardiology, garnered responses from more than 150 cardiologists around key factors driving treatment choices for patients with symptomatic severe aortic stenosis.

New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients

DUBLIN, May 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) announced today that it will report financial results for its fourth quarter and full fiscal year 2021 on Thursday, May 27, 2021. A news release will be issued at approximately 5:45 a.m.

Medtronic to Announce Financial Results for its Fourth Quarter and Full Fiscal Year 2021

DUBLIN and MINNEAPOLIS, May 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) and the Medtronic Foundation announced an additional $3M USD for COVID-19 relief efforts – a combination of financial resources, personal protective equipment (PPE) donations, and Medtronic employee engagement – focused on underserved areas of India, Brazil, the United States, and other global regions. This latest COVID-19 response expands Medtronic and Medtronic Foundation's COVID-19 support to $56M USD.

Medtronic and Medtronic Foundation Partner to Address COVID-19 Surges with Focus on Equity

Medtronic's (MDT) first patient-centric digital health platform is expected to provide better outcome for patients undergoing the company's SCS therapy.

Medtronic (MDT) to Enhance Patient Care via Digital Portal

DUBLIN, May 10, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of the SonarMed™ airway monitoring system. The first and only device of its kind, the SonarMed airway monitoring system utilizes acoustic technology to check for endotracheal tube (ETT) obstruction and verify position in real-time, giving clinicians vital information required to make more informed, life-saving decisions for their smallest patients.

Medtronic Launches New Pediatric Monitor That Alerts Clinicians To Potential Airway Obstructions During Ventilation

Cardinal Health

Chubb

Clorox

Costco

Chevron

Kinder Morgan

Leggett & Platt

Lockheed Martin

Northrop Grumman

Procter & Gamble

Travelers

Dividend stocks continue to amaze. If the goal is to produce a passive income stream that will one day cover our expenses, making sure that income stream grows is critical.

6 Dividend Increases Expected In May 2021

DUBLIN, May 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. The patient's care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient's experience with spinal cord stimulation.

Medtronic Announces CareGuidePro™, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey

As TAVI Patient Population Grows, PRO+ TAVI System Launches with Four Valve Sizes and Lowest Delivery Profile DUBLIN, May 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™ PRO+ TAVI System – the newest-generation Medtronic TAVI system that builds off the proven self-expanding, supra-annular Evolut TAVI platform. The Evolut PRO+ TAVI System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest annular range (for self-expanding TAVI technology) on the market.

Medtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe

DUBLIN, April 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced results from an interim analysis of the first 171 patients (including 71 roll-ins) treated in the OPTIMIZE PRO clinical study. The post-market, prospective, multi-center study is evaluating procedural outcomes (including pacemaker rate) associated with procedure-related techniques and post-procedure TAVR care pathways when using the self-expanding, supra-annular Evolut™ PRO and PRO+ TAVR systems in patients with symptomatic severe aortic stenosis.

Procedure-Related Techniques and Care Pathways from the OPTIMIZE PRO Clinical Study Show Promising Early Outcomes for Patients Implanted with the Medtronic Evolut™ TAVR System

Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function DUBLIN, April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Emprint™ ablation catheter kit – an investigational device not yet approved or cleared in the United States. The catheter is intended to be used in conjunction with the Emprint™ microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.

News for Medtronic Stock (MDT)